Trial Profile
Ofatumumab Early Treatment for High-Risk Treatment-Naive, Early Stage (0-II) Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2023
Price :
$35
*
At a glance
- Drugs Ofatumumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 30 Mar 2023 Status changed from active, no longer recruiting to completed.
- 24 May 2019 Planned End Date changed from 1 Mar 2022 to 1 Mar 2023.
- 11 Apr 2019 Planned End Date changed from 1 Mar 2019 to 1 Mar 2022.